×
About 14,503 results

ALLMedicine™ Cholangiocarcinoma Center

Research & Reviews  4,834 results

Cancer in Ecuadorian subjects with Laron syndrome (ELS).
https://doi.org/10.1530/ERC-22-0389
Endocrine-related Cancer; Guevara-Aguirre J, Peña G et. al.

Mar 28th, 2023 - 2018-2022 meta-analysis have shown that obesity increases the risk of various cancers such as acute myeloid lymphoma, chronic myeloid lymphoma, diffuse beta cell lymphoma, Hodgkin's lymphoma, leukemia, multiple myeloma, non-Hodgkin's lymphoma, bla...

Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combine...
https://doi.org/10.1007/s00432-023-04704-3
Journal of Cancer Research and Clinical Oncology; Jang YJ, Kim EJ et. al.

Mar 28th, 2023 - Immune checkpoint inhibitors (ICIs) have been demonstrated to be effective for unresectable or metastatic hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCA) in prior prospective trials. However, the clinical outcomes of ICIs in patients wi...

ASO Author Reflections: Long-Term Outcomes and Optimal Margin Width Among Patients Unde...
https://doi.org/10.1245/s10434-023-13351-4
Annals of Surgical Oncology; Alaimo L, Moazzam Z et. al.

Mar 26th, 2023 - ASO Author Reflections: Long-Term Outcomes and Optimal Margin Width Among Patients Undergoing Hepatectomy for Intrahepatic Cholangiocarcinoma.|2023|Alaimo L,Moazzam Z,Pawlik TM,|

Risk Factors of Cancer in Paediatric-onset Inflammatory Bowel Disease in Denmark and Fi...
https://doi.org/10.1097/MPG.0000000000003781
Journal of Pediatric Gastroenterology and Nutrition; Malham M, Jansson S et. al.

Mar 25th, 2023 - Paediatric-onset inflammatory bowel disease (pIBD) increases the risk of developing several different cancer forms. In this case-control study, we aimed to assess the impact of medical treatment and disease activity on the risk of developing disea...

Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator.
https://doi.org/10.1093/oncolo/oyad005
The Oncologist; Stenzinger A, Cuffel B et. al.

Mar 25th, 2023 - Adoption of high-throughput, gene panel-based, next-generation sequencing (NGS) into routine cancer care is widely supported, but hampered by concerns about cost. To inform policies regarding genomic testing strategies, we propose a simple metric,...

see more →

Guidelines  10 results

External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice G...
https://doi.org/10.1016/j.prro.2021.09.004
Practical Radiation Oncology; Apisarnthanarax S, Barry A et. al.

Oct 25th, 2021 - This guideline provides evidence-based recommendations for the indications and technique-dose of external beam radiation therapy (EBRT) in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC). The American Society for Radiation...

Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2021.0022
Journal of the National Comprehensive Cancer Network : JN... Benson AB, D'Angelica MI et. al.

May 25th, 2021 - The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts (intrahepatic and extrahepatic cholangiocarcino...

Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd ...
https://doi.org/10.1002/jhbp.870
Journal of Hepato-biliary-pancreatic Sciences; Nagino M, Hirano S et. al.

Dec 2nd, 2020 - The Japanese Society of Hepato-Biliary-Pancreatic Surgery launched the clinical practice guidelines for the management of biliary tract cancers (cholangiocarcinoma, gallbladder cancer, and ampullary cancer) in 2007, then published the 2nd version ...

AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With...
https://doi.org/10.1016/j.cgh.2019.07.011
Clinical Gastroenterology and Hepatology : the Official C... Bowlus CL, Lim JK et. al.

Jul 16th, 2019 - The purpose of this clinical practice update is to define key principles in the surveillance of hepatobiliary cancers including cholangiocarcinoma, gallbladder adenocarcinoma, and hepatocellular carcinoma in patients with primary sclerosing cholan...

Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline.
https://doi.org/10.1200/JCO.18.02178
Journal of Clinical Oncology : Official Journal of the Am... Shroff RT, Kennedy EB et. al.

Mar 12th, 2019 - To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer. ASCO convened an Expert Panel to conduct a systematic review of the literature on adjuvant therapy for ...

see more →

Drugs  4 results see all →

Clinicaltrials.gov  472 results

Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
https://clinicaltrials.gov/ct2/show/NCT04507503

Mar 24th, 2023 - This is an open-label study to provide expanded access to TAS-120 prior to its commercial availability for patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements who have failed standard therapy or who are unable to tolerate...

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
https://clinicaltrials.gov/ct2/show/NCT03412877

Mar 23rd, 2023 - Background: The administration of autologous tumor-infiltrating lymphocytes (TIL) can mediate complete, durable regressions in 20-25% of participants with metastatic melanoma. Recent studies have shown that these TIL predominantly recognize unique...

A Study of ICP-192 in Patients With Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04565275

Mar 14th, 2023 - Part I (Phase I) of the study enrolls patients with advanced solid tumors (9-15 patients); Part II (Phase II) of the study enrolls patients with urothelial carcinoma or cholangiocarcinoma with FGFR genetic alterations (30 patients).

Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)
https://clinicaltrials.gov/ct2/show/NCT04989218

Mar 13th, 2023 - All enrolled participants will receive the study intervention. Patients will receive up to 4 cycles of interventional agents prior to surgical resection. They will undergo imaging scans after the 2nd and 4th cycle (before surgery) of intervention ...

Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04301011

Mar 10th, 2023 - This is a Phase 1/2a dose escalation study with TBio-6517 administered by direct injection into tumor(s) or by intravenous infusion. The Phase 1 portion has 4 arms; the first arm (Arm A) will determine the RP2D of TBio-6517 alone when directly inj...

see more →

News  461 results

Understanding Cholangiocarcinoma: How Biomarker Testing Can Lead to a Targeted Treatment for Patients
https://www.mdedge.com/hematology-oncology/article/260788/understanding-cholangiocarcinoma-how-biomarker-testing-can-lead
Dr. Vaibhav Sahai, MD, MS

Feb 13th, 2023 - PEMAZYRE® (pemigatinib) is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected b.

Genomics data reveal promising PSC therapeutic target
https://www.mdedge.com/gihepnews/article/260476/pancreas-and-biliary-tract/genomics-data-reveal-promising-psc-therapeutic
Tara Haelle, MDedge News

Jan 4th, 2023 - An investigation of genomics data related to primary sclerosing cholangitis (PSC) in published medical literature revealed several genes likely involved in the pathogenesis of this autoimmune diseases, according to a study published in Gastro Hep.

FGFR2 Inhibitor RLY-4008 Appears Durable, Tolerable in Cholangiocarcinoma
https://www.onclive.com/view/fgfr2-inhibitor-rly-4008-appears-durable-tolerable-in-cholangiocarcinoma

Nov 23rd, 2022 - RLY-4008, a highly selective FGFR2 inhibitor, has demonstrated promising efficacy in patients with FGFR2-altered cholangiocarcinoma, while sparing patients the adverse effects (AEs) typically seen with pan-FGFR inhibitors, according to Suneel Kama...

Tumor Profiling Studies Illuminate Nuances Across Malignancies
https://www.onclive.com/view/tumor-profiling-studies-illuminate-nuances-across-malignancies

Nov 21st, 2022 - Molecular and immune landscapes for solid tumors are constantly evolving as precision medicine techniques become more sensitive and next-generation sequencing methods (NGS) are taken up in clinical practice. Posters presented at the European Soc...

Chronic HBV Infections Associated With a Range of Liver Malignancies
https://www.medscape.com/viewarticle/983968

Nov 12th, 2022 - Untreated chronic hepatitis B infections are associated with increased risks of most major extrahepatic cancer types, shows a new study conducted in South Korea. In this study, which was published in the Journal of Clinical Oncology, researchers f...

see more →

Patient Education  20 results see all →